NEUVOGEN宣布将在美国癌症研究协会年会上进行海报展示-动脉网

NEUVOGEN Announces Poster Presentation at the American Association of Cancer Research Annual Meeting

CISION 等信源发布 2025-04-30 02:06



可切换为仅中文







SAN DIEGO

圣地亚哥

，

April 29, 2025

2025年4月29日

/PRNewswire/ -- NEUVOGEN, Inc. ('NEUVOGEN THERAPEUTICS' or 'NEUVOGEN'), a

/PRNewswire/ -- NEUVOGEN, Inc.（“NEUVOGEN THERAPEUTICS”或“NEUVOGEN”），一家

San Diego

圣地亚哥

based biotechnology company, will present data that its next generation whole tumor cell vaccine (NGEN-143) activates T cells that recognize a diverse antigen repertoire.

基于生物技术的公司，将展示其下一代全肿瘤细胞疫苗（NGEN-143）激活识别多种抗原的T细胞的数据。

'These findings support that NGEN-143 can deliver an unprecedented breadth of targets and activate cytotoxic T cells, as compared to other currently available cancer vaccines, making NGEN-143 a better potential option for patients' said

“这些研究结果表明，与目前其他可用的癌症疫苗相比，NGEN-143能够带来前所未有的广泛靶点并激活细胞毒性T细胞，这使得NGEN-143成为患者更好的潜在选择。”

Todd Binder

托德·宾德

, Chief Executive Officer of NEUVOGEN. 'Our dedicated team is eager to bring this new cancer vaccine forward to treat patients with non-small cell lung cancer (NSCLC).'

NEUVOGEN的首席执行官表示：“我们专注的团队渴望推动这种新型癌症疫苗的发展，以治疗非小细胞肺癌（NSCLC）患者。”

Key Findings:

主要发现：

In a fully human in vitro system, NGEN-143 expands effector T cells against a broad repertoire of both tumor-associated antigens and common shared neo-antigens across a wide range of HLA types.

在完全人体的体外系统中，NGEN-143 能够扩增效应 T 细胞，针对广泛 HLA 类型的多种肿瘤相关抗原和常见共享新抗原。

NGEN-143 activates polyfunctional, cytotoxic T cells; the response is dominated by CD8+ cells without any evidence of antigenic competition. CD4+ T cell responses are skewed toward CD4+ Th1 cells over CD4+ Th2 cells.

NGEN-143激活多功能、细胞毒性的T细胞；反应以CD8+细胞为主，没有任何抗原竞争的证据。CD4+ T细胞反应倾向于CD4+ Th1细胞而非CD4+ Th2细胞。

NGEN-143 activated T cells efficiently kill human tumor cells in a caspase-3 dependent manner.

NGEN-143激活的T细胞以依赖caspase-3的方式有效杀死人类肿瘤细胞。

In the 'immune warm' CT26 mouse tumor model, vaccine abrogates or slows tumor growth – durable protection against rechallenge supports efficient induction of immune memory; vaccine + αPD1 improved survival over αPD1 monotherapy.

在“免疫温热”CT26小鼠肿瘤模型中，疫苗消除了肿瘤生长或减缓了其速度——对再次攻击的持久保护表明有效诱导了免疫记忆；疫苗+αPD1相比αPD1单药治疗提高了生存率。

In the 'immune cold' B16F10 mouse tumor model, our vaccine approach inhibits tumor growth and prolongs survival; vaccine + αPD1 improved survival.

在“免疫冷”B16F10小鼠肿瘤模型中，我们的疫苗方法抑制了肿瘤生长并延长了生存期；疫苗 + αPD1进一步提高了生存率。

Bernadette Ferraro

贝尔纳黛特·费拉罗

, Ph.D., NEUVOGEN's Vice President, Immuno-oncology, is scheduled to present 'An optimized off-the-shelf whole tumor cell vaccine activates T cells that recognize a diverse antigen repertoire with potential to provide meaningful clinical benefit to patients with NSCLC,' at AACR on

博士，NEUVOGEN的副总裁，免疫肿瘤学，计划在AACR上发表题为“一种优化的现成全肿瘤细胞疫苗激活T细胞，识别多样化的抗原谱，有望为NSCLC患者提供有意义的临床益处”的演讲。

Tuesday, April 29

4月29日，星期二

from 2:00 –

从2:00开始——

5:00 PM CT

下午5:00 中部时间

. A copy of the poster will be made available for download at neuvogen.com/our-science after the meeting concludes.

会议结束后，海报的副本将可在 neuvogen.com/our-science 下载。

About NEUVOGEN

关于NEUVOGEN

NEUVOGEN, Inc. is a

NEUVOGEN公司是一家

San-Diego

圣地亚哥

based biotechnology company focused on developing whole cell cancer vaccine therapies. NEUVOGEN believes its cancer vaccines have the broadest combination of tumor associated antigens and tumor specific antigens delivered in a cancer vaccine. As a result, these next-generation cancer vaccines can directly target a greater percentage of cancer cells in a solid tumor than any previous cancer vaccine.

基于生物技术的公司，专注于开发全细胞癌症疫苗疗法。NEUVOGEN相信其癌症疫苗在肿瘤相关抗原和肿瘤特异性抗原的组合上是目前最广泛的。因此，这些下一代癌症疫苗能够比以往任何癌症疫苗更直接地靶向实体瘤中更大比例的癌细胞。

NEUVOGEN's goal is to develop therapeutic cancer vaccines that activate the body's immune system to treat primary tumors, micrometastases, and metastases. In turn, these agents can delay and prevent relapses in early and late-stage disease and meaningfully extend the lives of patients with minimal side effects..

NEUVOGEN的目标是开发治疗性癌症疫苗，激活身体的免疫系统以治疗原发性肿瘤、微小转移灶和转移灶。这些药物可以延缓并预防早期和晚期疾病的复发，并在产生最少副作用的情况下有效延长患者的生命。

About NGEN-143

关于NGEN-143

NGEN-143 is NEUVOGEN's lead product candidate engineered for use in patients with non-small cell lung cancer. NGEN-143 is comprised of six allogeneic tumor cell lines genetically modified to include NEUVOGEN's proprietary activation technology and to increase the breadth of available tumor antigens.

NGEN-143是NEUVOGEN公司的主要候选产品，专为非小细胞肺癌患者设计。NGEN-143由六个经过基因改造的同种异体肿瘤细胞系组成，这些细胞系包含了NEUVOGEN专有的激活技术，并增加了可用肿瘤抗原的广度。

NGEN-143 is an off-the-shelf product enabling access to a broader range of patients..

NGEN-143是一种现成的产品，能够使更广泛的患者获得使用机会。

To learn more, visit

要了解更多信息，请访问

www.neuvogen.com

。

Media Contact

媒体联系人

media@Neuvogen.com

媒体@Neuvogen.com

SOURCE NEUVOGEN, Inc.